Temozolomide: Expanding its role in brain cancer

Drugs of Today

Volumn 46, Issue 11, 2010, Pages 833-846

  Mrugala, Maciej M ^a,b   Adair, J ^b   Kiem, H P ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 ( 3 METHYLTRIAZEN 1 YL)IMIDAZOLE 4 CARBOXAMIDE; 6 O BENZYLGUANINE; ALKYLATING AGENT; ANTICONVULSIVE AGENT; ANTINEOPLASTIC AGENT; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; ETOPOSIDE; FLUOROURACIL; IMIDAZOLE DERIVATIVE; INDOMETACIN; LOMEGUATRIB; LOMUSTINE; MARIMASTAT; METHOTREXATE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; MITOZOLOMIDE; NITROSOUREA DERIVATIVE; POLIFEPROSAN 20; POLYGLACTIN; PREDNISONE; RITUXIMAB; SORAFENIB; STEROID; TEMOZOLOMIDE; UNCLASSIFIED DRUG; VINCRISTINE; DRUG DERIVATIVE;

ADD ON THERAPY; ADJUVANT THERAPY; AGING; APOPTOSIS; ARTHRALGIA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BRAIN CANCER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER SURGERY; CELL DEATH; CEREBROSPINAL FLUID INFECTION; CLINICAL TRIAL (TOPIC); CONTINUOUS INFUSION; CYTOTOXICITY; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DNA METHYLATION; DNA REPAIR; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ELIMINATION; DRUG HYDROLYSIS; DRUG MEGADOSE; DRUG PENETRATION; DRUG RELEASE; DRUG SAFETY; DRUG SYNTHESIS; DRUG TOLERABILITY; GASTROINTESTINAL TOXICITY; GLIOBLASTOMA; GLIOMA; HISTOPATHOLOGY; HUMAN; HYDROCEPHALUS; IN VITRO STUDY; IN VIVO STUDY; LIQUORRHEA; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; MELANOMA; MULTIPLE CYCLE TREATMENT; NEUROSURGERY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; PROGRESSION FREE SURVIVAL; REVIEW; SINGLE DRUG DOSE; TENDON PAIN; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR RECURRENCE; AGED; ANIMAL; BRAIN TUMOR; CENTRAL NERVOUS SYSTEM TUMOR; DRUG RESISTANCE; PATHOLOGY;

AGED; ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; CENTRAL NERVOUS SYSTEM NEOPLASMS; DACARBAZINE; DRUG RESISTANCE, NEOPLASM; GLIOMA; HUMANS;

EID: 79955825992     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2010.46.11.1549024     Document Type: Review

References (92)

1. Central Brain Tumor Registry of the United States. 2010 CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2004-2006. http://www.cbtrus.org/2010-NPCR-SEER/CBTRUS- WEBREPORT-Final-3-2-10.pdf. Accessed December 13, 2010.
2. Newton, H., Malkin, M. (Eds.). Neurologic Complications of Systemic Cancer and Antineoplastic Therapy. 1st edition. Informa 2010.
3. Gerstner, E.R., Batchelor, T.T. Primary central nervous system lymphoma. Arch Neurol 2010, 67(3): 291-7.
4. Yung, W.K., Prados, M.D., Yaya-Tur, R. et al. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J Clin Oncol 1999, 17(9): 2762-71.
5. Stupp, R., Mason, W.P., van den Bent, M.J. et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005, 352(10): 987-96.
6. Stupp, R., Hegi, M.E., Mason, W.P. et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-Year analysis of the EORTC-NCIC trial. Lancet Oncol 2009, 10(5): 459-66.
7. Hegi, M.E., Diserens, A.C., Gorlia, T. et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005, 352(10): 997-1003.
8. Abrey, L.E., Olson, J.D., Raizer, J.J., Mack, M., Rodavitch, A., Boutros, D.Y., Malkin, M.G. A phase II trial of temozolomide for patients with recurrent or progressive brain metastases. J Neurooncol 2001, 53(3): 259-65.
9. Antonadou, D., Paraskevaidis, M., Sarris, G., Coliarakis, N., Economou, I., Karageorgis, P., Throuvalas, N. Phase II randomized trial of temozolomide and concurrent radiotherapy in patients with brain metastases. J Clin Oncol 2002, 20(17): 3644-50.
10. Christodoulou, C., Bafaloukos, D., Kosmidis, P. et al. Phase II study of temozolomide in heavily pretreated cancer patients with brain metastases. Ann Oncol 2001, 12(2): 249-54.
11. Addeo, R., Caraglia, M., Faiola, V. et al. Concomitant treatment of brain metastasis with whole brain radiotherapy [WBRT] and temozolomide [TMZ] is active and improves quality of life. BMC Cancer 2007, 7: 18.
12. Enting, R.H., Demopoulos, A., DeAngelis, L.M., Abrey, L.E. Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide. Neurology 2004, 63(5): 901-3.
13. Gerstner, E., Hochberg, F., Plotkin, S., Eichler, A., Batchelor, T. High-dose methotrexate, rituximab, and temozolomide (M/R/T) for patients with primary CNS lymphoma (PCNSL). Neuro-Oncology [2009 Jt Meet Soc Neuro-Oncol Am Assoc Neurol Surg/Congr Neurol Surg Sec Tumors (Oct 22-24, New Orleans) 2009] 2009, 11(5): Abst 275.
14. Reni, M., Mason, W., Zaja, F. et al. Salvage chemotherapy with temozolomide in primary CNS lymphomas: Preliminary results of a phase II trial. Eur J Cancer 2004, 40(11): 1682-8.
15. Wong, E.T. Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide. Neurology 2005, 64(5): 934; author reply
16. Newlands, E.S., Stevens, M.F., Wedge, S.R., Wheelhouse, R.T., Brock, C. Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat Rev 1997, 23(1): 35-61.
17. Newlands, E.S., Blackledge, G., Slack, J.A., Goddard, C., Brindley, C.J., Holden, L., Stevens, M.F. Phase I clinical trial of mitozolomide. Cancer Treat Rep 1985, 69(7-8): 801-5.
18. Hotta, T., Saito, Y., Fujita, H. et al. O6-alkylguanine-DNA alkyltransferase activity of human malignant glioma and its clinical implications. J Neurooncol 1994, 21(2): 135-40.
19. Gerson, S.L. MGMT: Its role in cancer aetiology and cancer therapeutics. Nat Rev Cancer 2004, 4(4): 296-307.
20. Tolcher, A.W., Gerson, S.L., Denis, L. et al. Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules. Br J Cancer 2003, 88(7): 1004-11.
21. Dresemann, G. Temozolomide in malignant glioma. Onco Targets Ther, 3: 139-46.
22. Central Brain Tumor Registry of the United States (CBTRUS). http://www.cbtrus.org/index.html. Accessed
23. Louis, D.N., Ohgaki, H., Wiestier, O.D., Cavenee, W.K. (Eds.). WHO Classification of Tumours of the Central Nervous System. IARC: Lyon, France 2007.
24. van Rijn, J., Heimans, J.J., van den Berg, J., van der Valk, P., Slotman, B.J. Survival of human glioma cells treated with various combination of temozolomide and X-rays. Int J Radiat Oncol Biol Phys 2000, 47(3): 779-84.
25. Stupp, R., Dietrich, P.Y., Ostermann Kraljevic, S. et al. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol 2002, 20(5): 1375-82.
26. Brada, M., Ashley, S., Dowe, A. et al. Neoadjuvant phase II multicentre study of new agents in patients with malignant glioma after minimal surgery. Report of a cohort of 187 patients treated with temozolomide. Ann Oncol 2005, 16(6): 942-9.
27. Chang, S.M., Prados, M.D., Yung, W.K. et al. Phase II study of neoadjuvant 1,3-bis(2-chloroethyl)-1-nitrosourea and temozolomide for newly diagnosed anaplastic glioma: A North American Brain Tumor Consortium Trial. Cancer 2004, 100(8): 1712-6.
28. Yung, W.K., Albright, R.E., Olson, J. et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 2000, 83(5): 588-93.
29. Brada, M., Hoang-Xuan, K., Rampling, R. et al. Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. Ann Oncol 2001, 12(2): 259-66.
30. Wong, E.T., Hess, K.R., Gleason, M.J. et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 1999, 17(8): 2572-8.
31. Herrlinger, U., Rieger, J., Koch, D. et al. Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03. J Clin Oncol 2006, 24(27): 4412-7.
32. Athanassiou, H., Synodinou, M., Maragoudakis, E. et al. Randomized phase II study of temozolomide and radiotherapy compared with radiotherapy alone in newly diagnosed glioblastoma multiforme. J Clin Oncol 2005, 23(10): 2372-7.
33. Groves, M.D., Puduvalli, V.K., Chang, S.M. et al. A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme. J Neurooncol 2007, 81(3): 271-7.
34. Brandes, A.A., Basso, U., Reni, M. et al. First-line chemotherapy with cisplatin plus fractionated temozolomide in recurrent glioblastoma multiforme: A phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia. J Clin Oncol 2004, 22(9): 1598-604.
35. Chua, S.L., Rosenthal, M.A., Wong, S.S., Ashley, D.M., Woods, A.M., Dowling, A., Cher, L.M. Phase 2 study of temozolomide and Caelyx in patients with recurrent glioblastoma multiforme. Neuro Oncol 2004, 6(1): 38-43.
36. Groves, M.D., Puduvalli, V.K., Hess, K.R., Jaeckle, K.A., Peterson, P., Yung, W.K., Levin, V.A. Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme. J Clin Oncol 2002, 20(5): 1383-8.
37. Graves, M.D., Puduvalli, V.K., Conrad, C.A. et al. Phase II trial of temozolomide plus marimastat for recurrent anaplastic gliomas: A relationship among efficacy, joint toxicity and anticonvulsant status. J Neurooncol 2006, 80(1): 83-90.
38. Robinson, C.G., Palomo, J.M., Rahmathulla, G., McGraw, M., Donze, J., Liu, L., Vogelbaum, M.A. Effect of alternative temozolomide schedules on glioblastoma O(6)-methylguanine-DNA methyltransferase activity and survival. Br J Cancer 2010, 103(4): 498-504.
39. Clarke, J.L., Iwamoto, F.M., Sul, J. et al. Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma. J Clin Oncol 2009, 27(23): 3861-7.
40. Wick, A., Felsberg, J., Steinbach, J.P. et al. Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma. J Clin Oncol 2007, 25(22): 3357-61.
41. Weiler, M., Hartmann, C., Wiewrodt, D. et al. Chemoradiotherapy of newly diagnosed glioblastoma with intensified temozolomide. Int J Radiat Oncol Biol Phys 2010, 77(3): 670-6.
42. Brada, M., Gabe, R., Stenning, S., Thompson, L., Lee, S.M. A randomised trial of temozolomide vs PCV chemotherapy for recurrent malignant glioma (MRC BR12). 33rd Eur Soc Med Oncol (ESMO) Congr (Sept 12-16, Stockholm) 2008,
43. Franceschi, E., Omuro, A.M., Lassman, A.B., Demopoulos, A., Nolan, C., Abrey, L.E. Salvage temozolomide for prior temozolomide respondent. Cancer 2005, 104(11): 2473-6.
44. Wick, A., Pascher, C., Wick, W., Jauch, T., Weller, M., Bogdahn, U., Hau, P. Rechallenge with temozolomide in patients with recurrent gliomas. J Neurol 2009, 256(5): 734-41.
45. Dolan, M.E., Roy, S.K., Fasanmade, A.A., Paras, P.R., Schilsky, R.L., Ratain, M.J. O6-Benzylguanine in humans: Metabolic, pharmacokinetic, and pharmacodynamic findings. J Clin Oncol 1998, 16(5): 1803-10.
46. Rabik, C.A., Njoku, M.C., Dolan, M.E. Inactivation of O6-alkylguanine DNA alkyltransferase as a means to enhance chemotherapy. Cancer Treat Rev 2006, 32(4): 261-76.
47. Dolan, M.E., Mitchell, R.B., Mummert, C., Moschel, R.C., Pegg, A.E. Effect of O6-benzylguanine analogues on sensitivity of human tumor cells to the cytotoxic effects of alkylating agents. Cancer Res 1991, 51(13): 3367-72.
48. Bobola, M.S., Tseng, S.H., Blank, A., Berger, M.S., Silber, J.R. Role of O6-methylguanine-DNA methyltransferase in resistance of human brain tumor cell lines to the clinically relevant methylating agents temozolomide and streptozotocin. Clin Cancer Res 1996, 2(4): 735-41.
49. Wedge, S.R., Porteous, J.K., Newlands, E.S. 3-aminobenzamide and/or 06-benzylguanine evaluated as an adjuvant to temozolomide or BCNU treatment in cell lines of variable mismatch repair status and O6-alkylguanine-DNA alkyltransferase activity. Br J Cancer 1996, 74(7): 1030-6.
50. Friedman, H.S., Dolan, M.E., Pegg, A.E. et al. Activity of temozolomide in the treatment of central nervous system tumor xenografts. Cancer Res 1995, 55(13): 2853-7.
51. Weingart, J., Grossman, S.A., Carson, K.A. et al. Phase I trial of polifeprosan 20 with carmustine implant plus continuous infusion of Intravenous O6-benzylguanine in adults with recurrent malignant glioma: New approaches to brain tumor therapy CNS consortium trial. J Clin Oncol 2007, 25(4): 399-404.
52. Quinn, J.A., Desjardins, A., Weingart, J. et al. Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma. J Clin Oncol 2005, 23(28): 7178-87.
53. Quinn, J.A., Jiang, S.X., Reardon, D.A. et al. Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma. J Clin Oncol 2009, 27(8): 1262-7.
54. Quinn, J.A., Jiang, S.X., Carter, J. et al. Phase II trial of Gliadel plus O6-benzylguanine in adults with recurrent glioblastoma multiforme. Clin Cancer Res 2009, 15(3): 1064-8.
55. Ranson, M., Middleton, M.R., Bridgewater, J. et al. Lomeguatrib, a potent inhibitor of O6-alkylguanine-DNA-alkyltransferase: Phase I safety, pharmacodynamic, and pharmacokinetic trial and evaluation in combination with temozolomide in patients with advanced solid tumors. Clin Cancer Res 2006, 12(5): 1577-84.
56. Ranson, M., Hersey, P., Thompson, D. et al. Randomized trial of the combination of lomeguatrib and temozolomide compared with temozolomide alone in chemotherapy naive patients with metastatic cutaneous melanoma. J Clin Oncol 2007, 25(18): 2540-5.
57. Watson, A.J., Sabharwal, A., Thorncroft, M. et al. Tumor O(6)-methyiguanine-DNA methyltransferase inactivation by oral lomeguatrib. Clin Cancer Res 2010, 16(2): 743-9.
58. Neff, T., Horn, P.A., Peterson, L.J. et al. Methylguanlne methyltransferase-mediated in vivo selection and chemoprotection of allogeneic stem cells in a large-animal model. J Clin invest 2003, 112(10): 1581-8.
59. Neff, T., Beard, B.C., Peterson, L.J., Anandakumar, P., Thompson, J., Kiem, H.P. Polyclonal chemoprotection against temozolomide in a large-animal model of drug resistance gene therapy. Blood 2005, 105(3): 997-1002.
60. Beard, B.C., Sud, R., Keyser, K.A. et al. Long-term polyclonal and multllineage engraftment of methylguanine methyltransferase P140K gene-modified dog hematopoietic cells in primary and secondary recipients. Blood 2009, 113(21): 5094-103.
61. Beard, B.C., Trobridge, G.D., Ironside, C., McCune, J.S., Adair, J.E., Kiem, H.P. Efficient and stable MGMT-mediated selection of long-term repopulating stem cells in nonhuman primates. J Clin Invest 2010, 120(7): 2345-54.
62. Brem, S., Tyler, B., Li, K., Pradilla, G., Legnani, F., Caplan, J., Brem, H. Local delivery of temozolomide by biodegradable polymers is superior to oral administration in a rodent glioma model. Cancer Chemother Pharmacol 2007, 60(5): 643-50.
63. Zhang, H., Gao, S. Temozolomide/PLGA microparticles and antitumor activity against glioma C6 cancer cells in vitro. Int J Pharm 2007, 329(1-2): 122-8.
64. Zhang, Y.H., Zhang, H., Liu, J.M., Yue, Z.J. Temozolomide/PLGA microparticles: A new protocol for treatment of glioma in rats. Med Oncol 2010, Epub ahead of print.
65. Zhang, Y.H., Yue, Z.J., Zhang, H., Tang, G.S., Wang, Y., Liu, J.M. Temozolomide/PLGA microparticles plus vatalanib inhibits tumor growth and angiogenesis in an orthotopic glioma model. Eur J Pharm Biopharm 2010, 76(3): 371-5.
66. Glantz, M., Chamberlain, M., Liu, Q., Litofsky, N.S., Recht, L.D. Temozolomide as an alternative to irradiation for elderly patients with newly diagnosed malignant gliomas. Cancer 2003, 97(9): 2262-6.
67. Chinot, O.L., Barrie, M., Frauger, E. et al. Phase II study of temozolomide without radiotherapy in newly diagnosed glioblastoma multiforme in an elderly populations. Cancer 2004, 100(10): 2208-14.
68. Fiorica, F., Berretta, M., Colosimo, C. et al. Glioblastoma in elderly patients: safety and efficacy of adjuvant radiotherapy with concomitant temozolomide. Arch Gerontol Geriatr 2010, 51(1): 31-5.
69. Malmstrom, A., Gronberg, B., Stupp, R. et al. Glioblastoma in elderly pateints: health-related quality of life (HRQOL) in a randomized trial comparing 6-weeks of radiotherapy (RT) vs hypofractionaied RT over 2 weeks vs temozolomide chemotherapy (TMZ). Neuro-Oncology [9th Congr Eur Assoc Neuro-Oncology (EANO) (Sept 16-19, Maastricht) 2010] 2010, 12(Suppl. 3): O.66.
70. Perry, J.R., O'Callaghan, C.J., Ding, K. et al. A phase III randomized controlled trial of short-course radiotherapy with or without comcomitant and adjuvant temozolomide in elderly patients with glioblastoma multiforme. Neuro-Oncology [9th Congr Eur Assoc Neuro-Oncology (EANO) (Sept 16-19, Maastricht) 2010] 2010, 12(Suppl. 3): P072.
71. Wick, W., Engel, C., Combs, S.E. et al. NOA-08 randomized phase 111 trial of 1-week-on/1-week-off temozolomide versus involved-field radiotherapy in elderly (older than age 65) patients with newly diagnosed anaplastic astrocytoma or glioblastoma (Methusalem). J Clin Oncol [46th Annu Meet Am Soc Clin Oncol (ASCO) (June 4-8, Chicago) 2010] 2010, 28(15, Suppl.): LBA2001.
72. Reni, M., Ferreri, A.J., Landoni, C., Villa, E. Salvage therapy with temozolomide in an immunocompetent patient with primary brain lymphoma. J Natl Cancer Inst 2000, 92(7): 575-6.
73. Herrlinger, U., Kuker, W., Platten, M., Dichgans, J., Welter, M. First-line therapy with temozolomide induces regression of primary CNS lymphoma. Neurology 2002, 58(10): 1573-4.
74. Lerro, K.A., Lacy, J. Case report: A patient with primary CNS lymphoma treated with temozolomide to complete response. J Neurooncol 2002, 59(2): 165-8.
75. Wong, E.T., Tishler, R., Barron, L., Wu, J.K. Immunochemotherapy with rituximab and temozolomide for central nervous system lymphomas. Cancer 2004, 101(1): 139-45.
76. Kurzwelly, D., Glas, M., Roth, P. et al. Primary CNS lymphoma in the elderly: Temozolomide therapy and MGMT status. J Neurooncol 2009, 97(3): 389-92.
77. Boogerd, W., Dalesio, O., Bais, E.M., van der Sande, J.J. Response of brain metastases from breast cancer to systemic chemotherapy. Cancer 1992, 69(4): 972-80.
78. Rosner, D., Nemoto, T., Lane, W.W. Chemotherapy induces regression of brain metastases in breast carcinoma. Cancer 1986, 58(4): 832-9.
79. Lassman, A.B., Abrey, L.E., Shah, G.D., Panageas, K.S., Begemann, M., Malkin, M.G., Raizer, J.J. Systemic high-dose intravenous methotrexate for central nervous system metastases. J Neurooncol 2006, 78(3): 255-60.
80. Cocconi, G., Lottici, R., Bisagni, G. et al. Combination therapy with platinum and etoposide of brain metastases from breast carcinoma. Cancer Invest 1990, 8(3-4): 327-34.
81. Franciosi, V., Cocconi, G., Michiara, M. et al. Front-line chemotherapy with cisplatin and etoposide for patients with brain metastases from breast carcinoma, nonsmall cell lung carcinoma, or malignant melanoma: a prospective study. Cancer 1999, 85(7): 1599-605.
82. Trudeau, M.E., Crump, M., Charpentier, D., Yelle, L., Bordeleau, L., Matthews, S., Eisenhauer, E. Temozolomide in metastatic breast cancer (MBC): A phase II trial of the National Cancer Institute of Canada - Clinical Trials Group (NCIC-CTG). Ann Oncol 2006, 17(6): 952-6.
83. Christodoulou, C., Bafaloukos, D., Linardou, H. et al. Temozolomide (TMZ) combined with cisplatin (CDDP) in patients with brain metastases from solid tumors: A Hellenic Cooperative Oncology Group (HeCOG) Phase II study. J Neurooncol 2005, 71(1): 61-5.
84. Rivera, E., Meyers, C., Groves, M. et al. Phase I study of capecitabine in combination with temozolomide in the treatment of patients with brain metastases from breast carcinoma. Cancer 2006, 107(6): 1348-54.
85. Verger, E., Gil, M., Yaya, R. et al. Temozolomide and concomitant whole brain radiotherapy in patients with brain metastases: A phase II randomized trial. Int J Radiat Oncol Biol Phys 2005, 61(1): 185-91.
86. Mikkelsen, T., Anderson, J., Doyle, T.J., Croteau, D., Avedissian, R., Ryu, S., Schultz, L. Phase I/II dose escalation trial of concurrent temozolomide and whole brain radiation therapy for multiple brain metastasis. J Neurooncol 2010, 100(2): 241-7.
87. Krown, S.E., Niedzwiecki, D., Hwu, W.J., Hodgson, L., Houghton, A.N., Haluska, F.G. Phase II study of temozolomide and thalidomide in patients with metastatic melanoma in the brain: High rate of thromboembolic events (CALGB 500102). Cancer 2006, 107(8): 1883-90.
88. Boogerd, W., de Gast, G.C., Dalesio, O. Temozolomide in advanced malignant melanoma with small brain metastases: Can we withhold cranial irradiation? Cancer 2007, 109(2): 306-12.
89. Conill, C., Fernandez-Ibiza, J., Malvehy, J., Puig, S., Sanchez, M., Castel, T [Temozolomide in patients with melanoma brain metastases treated with whole brain irradiation]. Med Clin (Barc) 2004, 122(11): 413-5.
90. Schadendorf, D., Hauschild, A., Ugurel, S. et al. Dose-intensified bi-weekly temozolomide in patients with asymptomatic brain metastases from malignant melanoma: A phase II DeCOG/ADO study. Ann Oncol 2006, 17(10): 1592-7.
91. Amaravadi, R.K., Schuchter, L.M., McDermott, D.F. et al. Phase II trial of temozolomide and sorafenib in advanced melanoma patients with or without brain metastases. Clin Cancer Res 2009, 15(24): 7711-8.
92. Siena, S., Crino, L., Danova, M. et al. Dose-dense temozolomide regimen for the treatment of brain metastases from melanoma, breast cancer, or lung cancer not amenable to surgery or radiosurgery: A multicenter phase II study. Ann Oncol 2010,21(3): 655-61.